Home › Metastatic Cancer › Pennsylvania › Pittsburgh
Metastatic Cancer clinical trials in Pittsburgh, PA
31 studies for Metastatic Cancer are looking for participants at sites in and around Pittsburgh (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
RecruitingPhase 2
- UPMC-Magee Womens Hospital, Pittsburgh
- UPMC Hillman Cancer Center, Pittsburgh
- UPMC-Passavant Hospital, Pittsburgh
- and 3 more
Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RecruitingPhase 1/2
- University of Pittsburgh Medical Center, Pittsburgh
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
RecruitingPhase 2/3
- University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, Pittsburgh
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
RecruitingPhase 1
- University of Pittsburgh Medical Center, Pittsburgh
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
RecruitingPhase 3
- AHN Allegheny General Hospital, Pittsburgh
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- Allegheny Health Network, Pittsburgh
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
- UPMC Hillman Cancer Center ( Site 0014), Pittsburgh
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- Clinical Study Site, Pittsburgh
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
RecruitingPhase 3
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
RecruitingPhase 1
- Allegheny General Hospital, Pittsburgh
- University of Pittsburgh Medical Center, Pittsburgh
FOG-001 in Locally Advanced or Metastatic Solid Tumors
RecruitingPhase 1/2
- University of Pittsburgh Medical Center, Hillman Cancer Center, Pittsburgh
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
RecruitingPhase 1
- UPMC Hillman Cancer Center, Pittsburgh
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
RecruitingPhase 1/2
- UPMC Hillman Cancer Center, Pittsburgh
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)
RecruitingPhase 3
- Research Site, Pittsburgh
- Research Site, Pittsburgh
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecruitingPhase 1
- University of Pittsburg Medical Center _UPMC Hillman Cancer Center, Pittsburgh
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
RecruitingPhase 3
- AHN Cancer Center, Pittsburgh
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
RecruitingPhase 1
- University of Pittsburg Medical Center (UPCM), Pittsburgh
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
RecruitingPhase 2/3
- University of Pittsburgh Medical Center(UPMC)-Hillman Cancer Center, Pittsburgh
A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body
RecruitingPhase 1/2
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
RecruitingPhase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Window of Opportunity in Preserving Laryngeal Function Trial
RecruitingPhase 2
- UPMC Hillman Cancer, Pittsburgh
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
RecruitingPhase 3
- University of Pittsburgh Medical Center - Hillman Cancer Center, Pittsburgh
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
RecruitingPhase 2/3
- UPMC Hillman Cancer Center, Pittsburgh
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RecruitingPhase 1
- Hillman Cancer Center, Pittsburgh
Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)
RecruitingPhase 2
- Allegheny Health Network West Penn Hospital, Pittsburgh
Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen
RecruitingPhase 3
- University of Pittsburgh Medical Center-Hillman Cancer Center, Pittsburgh
Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
RecruitingPhase 1/2
- University of Pittsburgh, Pittsburgh
Metastatic Cancer trials in other cities
- Houston, TX104 studies
- New York City, NY93 studies
- Nashville, TN70 studies
- Boston, MA63 studies
- Los Angeles, CA57 studies
- St. Louis, MO54 studies
- Arlington, VA53 studies
- Philadelphia, PA46 studies
- Chicago, IL45 studies
- San Antonio, TX44 studies
- Washington, DC43 studies
- Dallas, TX42 studies
Other studies in Pittsburgh
- Non-Small Cell Lung Cancer48 studies
- Cancer (all types)41 studies
- Breast Cancer39 studies
- Colorectal Cancer32 studies
- Melanoma31 studies
- Ovarian Cancer30 studies
- Endometrial Cancer23 studies
- Prostate Cancer23 studies
- Lung Cancer23 studies
- Head and Neck Squamous Cell Carcinoma22 studies
- Stroke22 studies
- Depression22 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.